Policy Watch: 20 Regulatory Updates — April 25, 2026
This Policy Watch covers schedules of controlled substances placement April 2026 updates relevant to cannabis clinicians. The DEA's recent scheduling actions affect synthetic cannabinoids and other substances. These regulatory changes inform clinical and…
In the Mix: 9 More Articles — April 09, 2026
The psychedelics therapy pilot program is expanding as Connecticut anticipates FDA approval, signaling important regulatory shifts in 2026. This development highlights evolving drug policies relevant to cannabis and related therapies. Clinicians should…
New Lawsuit Targets Texas THC Rules | FOX 7 Austin Report
The texas thc lawsuit highlights ongoing legal challenges to restrictive cannabis regulations in Texas. This lawsuit could impact patient access to medical cannabis and THC limits. Clinicians and patients should stay informed about these evolving legal…
Policy Watch: DEA Scheduling Benzodiazepines and Synthetic Drugs — April 01, 2026
This April 01, 2026 policy watch covers DEA scheduling benzodiazepines 2026 updates impacting cannabis clinical practice. The DEA's placement of several benzodiazepine analogs in Schedule I affects co-prescription protocols. These regulatory changes…
CED Regulatory Digest, Since Last Digest, 2 items
Digest covering 2 recent regulatory items.
Policy Watch: 10 Regulatory Updates — March 20, 2026
The DEA rescheduled marijuana from Schedule I to Schedule III, recognizing its medical utility. This regulatory update impacts prescribing restrictions for healthcare providers. The dea rescheduled marijuana change is a significant development in…